We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




PD-L1 Expression Associated With Poorer Survival in Anal Squamous Cell Carcinoma

By LabMedica International staff writers
Posted on 27 Sep 2022
Print article
Image: The Dako Autostainer Link 48 ensures optimal staining results and offers a high slide and reagent capacity (Photo courtesy of Agilent)
Image: The Dako Autostainer Link 48 ensures optimal staining results and offers a high slide and reagent capacity (Photo courtesy of Agilent)

Although anal squamous cell carcinoma (ASCC) is a rare malignancy, making up only 0.5% of all cancer cases in the USA, disconcertingly, the annual incidence continues to rise both globally and in the USA.

There is a clear association between human papillomavirus and ASCC, with human papillomavirus 16 being the most frequent genotype associated with nearly 90% of cases. Despite morphologic similarities, association with human papillomavirus, and shared risk factors with cervical squamous cell carcinoma, molecular and biological outcome predictors for survival are still not understood and may differ from those in cervical squamous cell carcinoma.

Pathology and Laboratory Medicine Scientists at Emory University (Atlanta, GA; USA) assessed programmed death ligand-1 (PD-L1) expression in patients with ASCC and correlated it with clinicopathologic factors and clinical outcomes. The team retrieved paraffin-embedded blocks from 58 cases which were immunostained with PD-L1 mouse monoclonal antibody (Agilent Dako, Carpinteria, CA, USA). Four- to 5-micrometer-thick sections of formalin-fixed, paraffin-embedded tissue were tested for the presence of PD-L1 using the Dako PD-L1 IHC 22C3 pharmDx kit. All slides were loaded on a Dako Auto Stainer Link 48automated system and incubated with a mouse monoclonal antibody to PD-L1 or the negative control reagent.

The investigators reported that PD-L1 was positive in 24/51 cases (47%) by combined positive score and in 18/51 (35%) by tumor proportion score. The median cancer-specific survival and 5-year overall survival were significantly lower in PD-L1+ patients. Age, sex, HIV status, HIV viral load, stage, and cancer progression were not significantly different between the two groups. The CD4 count of more than 200/μL was significantly higher in PD-L1+ patients. PD-L1+ status remained statistically significant for worse overall survival on multivariate analysis. The majority (16/24 [67%]) of PD-L1+ cases had overall low scores of less than 10 of combined positive score (CPS) and 12/18 [67%] of tumor proportion score (TPS). The team also noted that 3/24 (13%) of CPS and 3/18 (17%) of TPS were higher than 25.

The authors concluded that that the median cancer-specific survival and 5-year overall survival were significantly lower in PD-L1+ patients than PD-L1− patients with ASCC. PD-L1 expression is an independent prognostic factor for worse overall survival and does not correlate with age, sex, tumor stage, HIV status, HIV viral load, and progression-free survival. HIV-positive patients with higher CD4 count were more likely to be PD-L1+. The study was published in the September 2022 issue of the journal Archives of Pathology and Laboratory Medicine.

Related Links:
Emory University 
Dako 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.